Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Current Deferred Revenue (2022 - 2025)

Historic Current Deferred Revenue for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q1 2025 value amounting to $3.0 million.

  • NewAmsterdam Pharma's Current Deferred Revenue fell 6266.63% to $3.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $3.0 million, marking a year-over-year decrease of 6266.63%. This contributed to the annual value of $6.0 million for FY2024, which is 3968.48% down from last year.
  • As of Q1 2025, NewAmsterdam Pharma's Current Deferred Revenue stood at $3.0 million, which was down 6266.63% from $6.0 million recorded in Q4 2024.
  • NewAmsterdam Pharma's Current Deferred Revenue's 5-year high stood at $18.7 million during Q4 2022, with a 5-year trough of $3.0 million in Q1 2025.
  • Moreover, its 4-year median value for Current Deferred Revenue was $6.1 million (2024), whereas its average is $8.0 million.
  • As far as peak fluctuations go, NewAmsterdam Pharma's Current Deferred Revenue tumbled by 3968.48% in 2024, and later plummeted by 6266.63% in 2025.
  • NewAmsterdam Pharma's Current Deferred Revenue (Quarter) stood at $18.7 million in 2022, then crashed by 46.64% to $10.0 million in 2023, then plummeted by 39.68% to $6.0 million in 2024, then plummeted by 49.57% to $3.0 million in 2025.
  • Its Current Deferred Revenue stands at $3.0 million for Q1 2025, versus $6.0 million for Q4 2024 and $4.5 million for Q3 2024.